Guidelines for ATC classification and DDD assignment - WHOCC

146
Lisuride tablets in high strength (0.2 mg) are classified in this group,
while low strength tablets (25 mcg) are classified in N02C -
Antimigraine preparations.
The DDDs are based on use as lactation inhibitors. The DDD for
parenteral depot formulations of bromocriptine is equal to the DDD
for oral administration, based on the assumption that the single dose
parenteral treatment equals 14 days of oral treatment.
G02CC Antiinflammatory products for vaginal administration
This group comprises e.g. non-steroidal antiinflammatory drugs for
vaginal administration.
G02CX Other gynecologicals
G03 SEX HORMONES AND MODULATORS OF THE GENITAL
SYSTEM
Other hormones, see H - Systemic hormonal preparations, excl. sex
hormones and insulins.
Sex hormones used only in the treatment of cancer (often selected
strengths) are classified in L - Antineoplastic and immunomodulating
agents.
The DDDs of many of the hormone preparations may vary
considerably with the route of administration due to substantial
differences in bioavailability. The DDDs of depot preparations are
calculated as the dose divided by the dosing interval.
G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
This group comprises hormonal preparations, which are used as
contraceptives. Similar hormonal preparations, which are used for the
treatment of e.g. menopausal symptoms and menstrual irregularities, are
classified in G03F.
Combinations of cyproterone and estrogen also used as contraceptives
are, however, classified in G03HB.